Don't forget about the below "private" email from one of our experienced biotech gamblers. ALWAYS REMEMBER THAT LEO NEVER PR'S BAD NEWS. HE SIMPLY EMAILS THE BAD NEWS TO A SINGLE SHAREHOLDER AND THEN LATER HIDES IT IN A SEC FILING.
"I just received a response from Leo, wanted to share immediately. His responses in bold:
Shareholders need to know what is happening with the company, given the unexplained problem with getting Prurisol results, We expect to update shareholders shortly. The anticipated sequence of news will be a) Data Lock, and b) thereafter, top-line results.
the toxic capital raise, We sold stock at a fixed price. Albeit low but we needed funds for production of Brilacidin for further studies and other clinical trial payables.
and lack of BTD or deal for Brlacidin-OM despite "excellent" results and saying negotiations were underway. Please anticipate our update as all this is being worked on.
The growing concern is that the company may have misled investors and fumbled the Prurisol trial. The trial will be unblinded shortly. It's a function of company resources allocated to each product."